Cilastazol is a 2-oxo-quinoline with vasodilator, antimitogenic, antithrombotic, and cardiotonic properties. This compound has been shown to cause inhibition of adenosine uptake, eventually resulting in changes to cAMP levels. Studies have shown Cilostazol to be a potent inhibitor of PDE3A (phosphodiesterase 3A) in vitro. PDE3A is often in the Cardiac system. In addition Cilastazol has also been observed to inhibit mitogenesis, migration of vascular smooth muscle cells, and platelet aggregation in vitro. Cilostazol displays a capacity to lower levels of serum triglycerides and cause some increase in HDL-cholesterol levels in vitro.
bvseo-msg: The resource to the URL or file is currently unavailable.;
Rated 5 out of
MatsumotoMatsumoto, et. al. (PubMed ID 15908466) found that cilostazol improved EDHF-type relaxations in streptozotocin-induced diabetic rats via an increae in cAMP and PKA signaling.
To place an order using RMB or to ship to mainland China, please visit www.scbio.cn